For in vitro diagnostic use. Others THC2 IVD THC2 CPS_000249 ONLINE DAT Cannabinoids II 08771669190 THC2, 150T, cobas c pack green THC2 07613336166239 Reagents, kits 150 tests cobas c 303/503 true 03046753190 COBAS INTEGRA CANNABINOIDS GEN II Cannabinoids II 04015630996667 Reagents, kits 200 tests COBAS INTEGRA 400 Plus true 04491009190 THC2, 200T, cobas c THC2 04015630997770 Reagents, kits 200 tests cobas c 311/501/502 true 05888557190 THC2, 100T, cobas c 701/702 THC2 04015630928378 Reagents, kits 100 tests cobas c 701/702 true 08058644190 THC2, 850T, cobas c pack green THC2 07613336121511 Reagents, kits 850 tests cobas c 303/503 true 0208058644190c503 THC2 ONLINE DAT Cannabinoids II en 4 FF00000006C6C30E FF00000005BBF00E 08058644190 08771669190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useCannabinoids II (THC2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of cannabinoids in human urine on cobas c systems at cutoff concentrations of 20 ng/mL, 50 ng/mL and 100 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1708058644190c503sp THC2 ONLINE DAT Cannabinoids II en 5 FF000000055FB30E FF000000055FB30E 08058644190 08771669190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useCannabinoids II (THCII) is an in vitro diagnostic test for the qualitative detection of cannabinoids in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 50 ng/mL. Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 08058644500 THC2 ONLINE DAT Cannabinoids II en 7 FF00000006F7260E FF000000055FC30E 08058644190 08771669190 10299 cobas c 703 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useApplication in urineCannabinoids II (THC2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of cannabinoids in human urine on cobas c systems at cutoff concentrations of 20 ng/mL, 50 ng/mL and 100 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. Application in serum and plasma**not available in all countriesCannabinoids II (THC2) is an in vitro diagnostic test for the qualitative detection of cannabinoids in human serum and plasma on cobas c systems at a cutoff concentration of 50 ng/mL. Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1708058644190c503sp THC2 ONLINE DAT Cannabinoids II en 2 FF000000041FC90E FF0000000385310E 08058644190 08771669190 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useCannabinoids II (THCII) is an in vitro diagnostic test for the qualitative detection of cannabinoids in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 50 ng/mL. Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0603046753190COIN THCII ONLINE DAT Cannabinoids II en 8 FF00000005AA5F0E FF00000005AA5F0E 03046753190 302 COBAS INTEGRA 400 plus Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useCannabinoids II (THCII) is an in vitro diagnostic test for the semiquantitative and qualitative detection of cannabinoids in human urine at cutoff concentrations of 20 ng/mL, 50 ng/mL, and 100 ng/mL on COBAS INTEGRA systems. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC/MS).Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0204491009190c501 THC2 ONLINE DAT Cannabinoids II en 14 FF00000006EA940E FF00000006EA940E 04491009190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useCannabinoids II (THC2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of cannabinoids in human urine on cobas c systems at cutoff concentrations of 20 ng/mL, 50 ng/mL and 100 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1704491009190c501sp THC2 ONLINE DAT Cannabinoids II en 4 FF000000048D6D0E FF00000001D5610E 04491009190 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useCannabinoids II (THCII) is an in vitro diagnostic test for the qualitative detection of cannabinoids in human serum and plasma on Roche/Hitachi cobas c systems at a cutoff concentration of 50 ng/mL. Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 04491009500 THC2 ONLINE DAT Cannabinoids II en 14 FF00000006C8170E FF00000000993B0E 04491009190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useApplication in urineCannabinoids II (THC2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of cannabinoids in human urine on cobas c systems at cutoff concentrations of 20 ng/mL, 50 ng/mL and 100 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.Application in serum and plasma**not available in all countriesCannabinoids II (THC2) is an in vitro diagnostic test for the qualitative detection of cannabinoids in human serum and plasma on cobas c systems at a cutoff concentration of 50 ng/mL. Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry(GC‑MS) or liquid chromatography coupled with tandem mass spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 05888557500 THC2 ONLINE DAT Cannabinoids II en 5 FF00000006CD0D0E FF000000009C890E 05888557190 2492 cobas c 702 310 cobas c 701 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useCannabinoids II (THC2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of cannabinoids in human urine on cobas c systems at cutoff concentrations of 20 ng/mL, 50 ng/mL and 100 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Cannabinoids II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en